Extracellular Vesicles and Nanoparticles: Mechanisms of Cellular Communication, Disease Regulation, and Biomarker Discovery

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cellular/Molecular Immunology".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 4306

Special Issue Editors


E-Mail Website
Guest Editor
Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Interests: extracellular vesicles biogenesis; infectious diseases; CNS, immunology; cell-to-cell communication; nanoparticle technology; biomarker discovery; EV-based therapeutics

E-Mail Website
Guest Editor
Department of Primary Appointment, School of Medicine, Silver Spring, MD 20910, USA
Interests: immunoprofiling of vaccine-induced responses; infectious diseases; vaccines; immunomodellling; adjuvants
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Extracellular vesicles (EVs) are increasingly identified as important players in the progression of disease by enhancing the underlying mechanisms of infection. Similarly, EVs may serve as transporters of biological “messages” allowing for the evasion of the immune system and targeting of specific cells. These observations suggest the existence of a highly orchestrated set of events in the donor cell, which may be deregulated by cancer, viruses, parasites, or bacteria, resulting in the generation and release of EVs with specific sets of associated cargo. There is extensive evidence of cargo, such as RNA and proteins, associated to EVs from diverse disease settings (e.g., cancer, neurodegeneration, autoimmune disorders) and infectious settings (e.g., viral, bacterial, and parasitic), and also about the heterogeneity of EVs based on size or cargo. In addition, the biogenesis of EVs is still not fully understood, in particular as it pertains to pathways that generate EVs with particular characteristics (i.e., size and cargo). Several nanoparticles that may resemble EVs are already being used in drug delivery or biomarker capture. Moreover, the use of nanoparticles as delivery systems and adjuvants for vaccines has been gaining an increasing amount of interest. Studies show that the use of these particles allows for a more direct delivery of the vaccine to the area of interest, a more specific and stronger immune response to the vaccine, and a time-release capability of the vaccine. It is possible that EVs can also serve to deliver cargo and to diagnose based on associated biomarkers that would indicate the intracellular state of cells. Additionally, EVs may be important players in cell-to-cell communication, operating at the interface between cellular factors and immune cells. The overall goal of this Special Issue is to bring together expertise from the fields of infectious diseases, cell-to-cell communication, immunology, CNS, diagnostics, biomarker discovery, and nanoparticle technology to elucidate the role of EVs in the interphase between the immune system, central nervous system (CNS), and disease progression.

This Special issue intends to bridge these diverse fields to promote future potential research in EV-based vaccines. Based on your expertise, we invite you to contribute with an original report, original observation or review, to highlight (i) mechanisms of EV biogenesis, (ii) immune pathways affected by EVs, (iii) mechanisms of EV invasion into the CNS, (iv) nanoparticle synthesis or use in diagnostics of disease, and (v) recent advances in EV-based therapeutics.

Dr. Daniel O. Pinto
Dr. Elke S. Bergmann-Leitner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • extracellular vesicles
  • exosomes
  • infectious disease
  • cancer
  • CNS
  • immune system
  • biogenesis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1668 KiB  
Review
The Potential of Exosomes in Allergy Immunotherapy
by Paul Engeroff and Monique Vogel
Vaccines 2022, 10(1), 133; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10010133 - 17 Jan 2022
Cited by 9 | Viewed by 3546
Abstract
Allergic diseases represent a global health and economic burden of increasing significance. The lack of disease-modifying therapies besides specific allergen immunotherapy (AIT) which is not available for all types of allergies, necessitates the study of novel therapeutic approaches. Exosomes are small endosome-derived vesicles [...] Read more.
Allergic diseases represent a global health and economic burden of increasing significance. The lack of disease-modifying therapies besides specific allergen immunotherapy (AIT) which is not available for all types of allergies, necessitates the study of novel therapeutic approaches. Exosomes are small endosome-derived vesicles delivering cargo between cells and thus allowing inter-cellular communication. Since immune cells make use of exosomes to boost, deviate, or suppress immune responses, exosomes are intriguing candidates for immunotherapy. Here, we review the role of exosomes in allergic sensitization and inflammation, and we discuss the mechanisms by which exosomes could potentially be used in immunotherapeutic approaches for the treatment of allergic diseases. We propose the following approaches: (a) Mast cell-derived exosomes expressing IgE receptor FcεRI could absorb IgE and down-regulate systemic IgE levels. (b) Tolerogenic exosomes could suppress allergic immune responses via induction of regulatory T cells. (c) Exosomes could promote TH1-like responses towards an allergen. (d) Exosomes could modulate IgE-facilitated antigen presentation. Full article
Show Figures

Figure 1

Back to TopTop